Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solvonis TherapeuticsSLVNF -58.33% EV-to-EBIT is -0.34 as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 380 Biotechnology companies, Solvonis Therapeutics ranks worse than 263157.63% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Solvonis Therapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Solvonis Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solvonis Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solvonis Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Solvonis Therapeutics's EV-to-EBIT falls into.
Solvonis Therapeutics's current Enterprise Value is $2.58 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solvonis Therapeutics (SLVNF) has a EV-to-EBIT of -0.34 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 380 companies in the Biotechnology industry.
Is Solvonis Therapeutics' EV-to-EBIT too high?
Solvonis Therapeutics' current EV-to-EBIT is -0.34. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' EV-to-EBIT compare to ?
According to the Biotechnology industry distribution chart, Solvonis Therapeutics ranks #999999 out of 380 companies for EV-to-EBIT. This places Solvonis Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.99, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solvonis Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current EV-to-EBIT is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Solvonis Therapeutics (SLVNF) has a current EV-to-EBIT of -0.34. The current EV-to-EBIT is -0.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Solvonis Therapeutics (SLVNF), the current EV-to-EBIT is -0.34 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLVNF has been successfully added to your 
